Your session is about to expire
← Back to Search
#HerHeart tool for Cardiovascular Disease
N/A
Waitlist Available
Led By Holly Gooding, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 month post-enrollment
Awards & highlights
Summary
This trial will test how well a web tool called #HerHeart works in helping adolescent and young adult women and their healthcare providers communicate about heart health.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 3 month post-enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 month post-enrollment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
#HerHEART Risk Score in AYA From Baseline
Alcohol Consumption
Cereal Fiber
+7 moreSecondary outcome measures
BMI From Baseline
Diastolic Blood Pressure (BP) From Baseline
Systolic Blood Pressure (BP) From Baseline
Trial Design
1Treatment groups
Experimental Treatment
Group I: AYA participantsExperimental Treatment1 Intervention
AYA participants will complete a brief initial survey consisting of demographic information and the Visual Analog Scale (VAS) and the #HerHeart tool in clinic. AYA participants will the rate the usability of the #HerHeart tool using the Website Analysis and Measurement Inventory (WAMMI), the likelihood they would recommend the app to their friends, and the likelihood of behavior change. AYA participants will then be offered the opportunity to continue into the 3-month intervention phase.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
#HerHeart tool
2022
N/A
~60
Find a Location
Who is running the clinical trial?
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,854 Previous Clinical Trials
47,817,812 Total Patients Enrolled
Emory UniversityLead Sponsor
1,655 Previous Clinical Trials
2,572,423 Total Patients Enrolled
Holly Gooding, MDPrincipal InvestigatorEmory University
Share this study with friends
Copy Link
Messenger